Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,230.71
(
-0.16%
)
Brent Oil
100.77
(
-0.75%
)
Bitcoin
79,040.70
(
0.49%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 241076

Thursday, 04/07/2022 10:58:35 AM

Thursday, April 07, 2022 10:58:35 AM

Post# of 257443
ANNX completes phase-2 enrollment for dry AMD—results in 1H23:

https://www.globenewswire.com/news-release/2022/04/07/2418284/0/en/Annexon-Biosciences-Completes-Enrollment-in-ARCHER-Phase-2-Trial-of-Novel-C1q-Inhibitor-ANX007-in-Patients-with-Geographic-Atrophy.html

Treatment of dry AMD is a major unmet need, and ANNX is currently trading at a market cap that is roughly half its cash on hand. (No position.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today